Clinical Trials

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06072781 2026-03-17

RAMP 301

270 enrolled

Low Grade Serous Ovarian Cancer

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07194044 2026-03-16

METTSEO

15 enrolled

Sarcoma, Ewing

NCT07214779 2026-03-16

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT06312176 2026-03-13

MK-2870-010

1,200 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

20 enrolled

Triple Negative Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT07125183 2026-02-05

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

20 enrolled

Leiomyosarcoma, Sarcoma

NCT04028063 2026-01-27

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

65 enrolled

NCT07218809 2026-01-16

TREVI-OC-01

1,100 enrolled

Carcinoma, Ovarian Epithelial

NCT06161025 2026-01-12

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

860 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03618550 2025-12-02

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT05271318 2025-11-03

PROTA

Phase 1/2 Recruiting

29 enrolled

Adenoviridae Infections

NCT06994195 2025-08-17

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

384 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT05029999 2025-08-13

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

30 enrolled

Breast Neoplasms

NCT06023862 2025-06-15

DOVE

198 enrolled

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06292286 2025-06-11

SCENIC

Phase NA Recruiting

18 enrolled

Ovarian Neoplasms

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05210374 2025-03-25

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

24 enrolled

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma

NCT06791460 2025-03-18

Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer

Phase 2/3 Recruiting

296 enrolled

Ovarian Cancer Recurrent

NCT05748834 2025-01-31

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

36 enrolled

Breast Neoplasms

NCT04516447 2024-11-26

A Study of ZN-c3 in Patients With Ovarian Cancer

140 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

372 enrolled

Breast Neoplasms

NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)